Page 6 - Flipbook
P. 6
Pembrolizumab vs Placebo as Post Nephrectomy Adjuvant Therapy for Patients with Renal Cell Carcinoma: Randomized, Double-Blind, Phase 3 KEYNOTE-564 Study
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
